SCHEMBL178819

SCHEMBL178819

COc1ccc(-c2cc(C)c3[nH]c4cc(OC)c(Cl)cc4c3n2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 3/20 0.47
KDM4E B2RXH2 6/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
ALDH1A1 P00352 5/20 0.41
MAPT P10636 4/20 0.41
HPGD P15428 4/20 0.41
HTT P42858 2/20 0.41
LMNA P02545 2/20 0.41
TP53 P04637 1/20 0.40
GAA P10253 1/20 0.40
POLB P06746 2/20 0.39
BLM P54132 1/20 0.39
DYRK1A Q13627 2/20 0.38
PDE10A Q9Y233 1/20 0.37
AURKA O14965 1/20 0.37
AURKB Q96GD4 1/20 0.37
DHODH Q02127 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL178818 0.83 JAK2 (0.65) JAK2KDM4EMEN1KMT2ANPC1
SCHEMBL139852 0.83 JAK2 (0.62) JAK2KDM4EDYRK1A
SCHEMBL141924 0.83 JAK2 (0.60) JAK2KDM4EMAPTTP53DHODH
SCHEMBL178707 0.73 JAK2 (0.69) JAK2KDM4EMEN1KMT2ANPC1
SCHEMBL26924148 0.68 KDM4E (0.47) KDM4EMEN1KMT2ANPC1RAB9A
SCHEMBL142655 0.67 JAK2 (0.78) JAK2KDM4ENPC1RAB9AALDH1A1
SCHEMBL3280681 0.66 PDE3B (0.52) JAK2KDM4EMEN1KMT2AALDH1A1
SCHEMBL31609272 0.66 MAPT (0.49) KDM4EMEN1KMT2ANPC1RAB9A
SCHEMBL142463 0.66 JAK2 (0.77) JAK2DYRK1A
SCHEMBL141522 0.66 JAK2 (0.80) JAK2KDM4ENPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS JAK2, JAK1, JAK3 JAK2 1/4885KDM4E 928/4885MEN1 2279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.